期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌肿瘤异质性及靶向药物治疗 被引量：5

暂未订购
导出
摘要 靶向药物选择性杀伤依赖靶分子的肿瘤细胞，较细胞毒类药物更为安全高效。用药前检测肿瘤组织靶分子表达水平或基因突变，预测药物敏感性指导用药，这种药物基因组学指导下的靶向药物治疗被认为是未来肿瘤个体化用药的方向。迄今已有多种靶向药物用于临床，
作者 薛丽 白玉杰
机构地区 海南医学院科学实验中心 海南医学院干细胞研究所
出处 《广东医学》 CAS CSCD 北大核心 2012年第16期2529-2531,共3页 Guangdong Medical Journal
基金 国家自然科学基金资助项目(编号:30760282)
关键词 肿瘤异质性 靶向药物 药物治疗 乳腺癌 细胞毒类药物 药物基因组学 选择性杀伤 药物敏感性
分类号 R730.2 [医药卫生—肿瘤]
  • 相关文献

参考文献27

  • 1SOTILLO R, SCHVARTZMAN J M, SOCCI N D, et al. Mad2 - induced chromosome instability leads to lung tumour relapse after oncogene withdrawal[ J]. Nature, 2010, 464(7287) : 436 -440.
  • 2FOX E J, SALK J J, LOEB L A. Cancer genome sequencing - an interim analysis[J]. Cancer Res, 2009, 69(12) : 4948 -4950.
  • 3YIP S, MIAO J, CAHILL D P, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temoznlo- mide resistance[ J ]. Clin Cancer Res, 2009, 15 (14) : 4622 - 4629.
  • 4KUNIMOTO K, INOUE S, ICHIHARA F, et al. A case of met- astatic breast cancer with outgrowth of Her 2 - negative ceils after eradication of Her - 2 positive cells by humanized anti - Her2 mon- oclonal antibody ( trastuzumab ) combined with docetaxel [ J ]. Hum Pathol, 2004, 35(3) : 379 -381.
  • 5PECTASIDES D, GAGLIA A, ARAPANTONT DADIOTI P, et al. HER -2/neu status of primary breast cancer and correspond- ing. meta static sites in patients with advanced breast cancer trea- ted with trastuzumab -based therapy[ J ]. Anticancer Res, 2006, 26(1B) :647 -653.
  • 6STAAF J, JOSSON G, RINGNER M, et al. High- resolution genom- ic and expression analyses of copy number alterations in HER2 - am- plified breast cancer[J]. Breast Cancer Res, 2010, 12(3) : R25.
  • 7NORMANNO N, CAMPIGLIO M, MAIELLO M R, et al. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling [J]. Breast Cancer Res Treat, 2008, 112( 1 ) : 25 -33.
  • 8NORMANNO N, DE LUCA A, MAIELLO M R, et al. The MEK/ MAPK pathway is involved in the resistance of breast cancer ceils to the EGFR tyrosine kinase inhibitor gefitinib[ J]. J Cell Physiol, 2006, 207 (2) : 420 - 427.
  • 9FAN M, YAN P S, HARTMAN FREY C, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer ceils to the antiestrogens tamoxifen and fulvestrant [ J ]. Cancer Res, 2006, 66 (24) : 11954 - 11966.
  • 10MAHESWARAN S, SEQUIST L V, NAGRATH S, et al. Detec- tion of mutations in EGFR in circulating lung - cancer cells [ J ]. N Engl J Med, 2008, 359(4) : 366 -377.

同被引文献35

  • 1Ochiai T, Nishimura K, Walanahe T, et al. Individualized chemo-therapy for colorectal cancer based on the collagen gel droplet - embedded drug sensitivity test [ J ]. Oncol Lett,2012,4 (4) : 621 - 624.
  • 2Mullins CS, Eisold S, Klar E, et al. Multidrug - resistance proteins are weak tumor associated antigens for colorectal carcinoma [ J ]. BMC Immunol,2011,12 :38.
  • 3Tsavaris N, Lazaris A, Kosmas C, et al. Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences fol- lowing 5 - fluorouracil - based adjuvant chemotherapy [ J ]. Cancer Chemother Pharmaco1,2009,64 ( 2 ) : 391 - 398.
  • 4Gilbert DC, Chalmers A J, E1 - Khamisy SF. Topoisomerase I inhibi- tion in colorectal cancer:biomarkers and therapeutic targets[ J]. Br J Cancer,2012,106 ( 1 ) : 18 - 24.
  • 5Kostopoulos I, Karavasilis V, Karina M, et al. Topoisomerase I but not thymidylate synthase is associated with improved outcome in pa- tients with reseeted colorectal cancer treated with irinotecan contai- ning adjuvant chemotherapy[ J]. BMC Cancer,2009,9:339.
  • 6Horikawa Y, Otaka M, Komatsu K, et al. MEK activation suppresses CPT11 -induced apoptosis in rat intestinal epithelial cells through a COX - 2 - dependent mechanism [ J ]. Dig Dis Sci, 2007,52 (10) :2757 -2765.
  • 7Romer MU, Nygard SB, Christensen I.I, et al. Topoisomerase 1 ( TOP1 ) gene copy number in stage Ⅲ colorectal cancer patients and its relation to prognosis[ J]. Mol Oncol,2013,7 (1) :101 - 111.
  • 8Ikeguchi M, Arai Y, Maeta Y, et al. Topoisomerase I expression in tumors as a biological marker for CPT - Ⅱ chemosensitivity in pa- tients with colorectal cancer[ J ]. Surg Today, 2011,41 (9) :1196 - 1199.
  • 9Heppner Gh. Tumor heterogeneity [ J ]. Cancer Res, 1984, 44 (6) : 2259 - 2265.
  • 10Berehuck A, Olt GJ, Soisson AP. Heterogeneity of antigen expression in advanced epithelial ovarian cancer [ J ]. Am J Obstet Gynecol, 1990, 162(4) : 883 -888.

引证文献5

二级引证文献6

广东医学
2012年 第16期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部